IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Examiner: Kemmerer, Elizabeth
Audrey Goddard et al.) Art Unit: 1646
Application Serial No. 09/902,713) Confirmation No. 1320
Filed: July 10, 2001) Attorney's Docket No. 39780-1618P2C34
For: ANTIBODIES TO PRO269 POLYPEPTIDES) Customer No. 35489)

EXPRESS MAIL LABEL NO. <u>EV 582 632 155 US</u>

DATE MAILED: AUGUST 21, 2006

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP RCE

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each publication other than U.S. patents and U.S. patent application publications, and each cited pending unpublished U.S. application along with a concise explanation of information in a foreign language pursuant to 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Form PTO-1449 is enclosed and the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

HELL	ER EHI	RMAN LLP	
Dated:	August	21, 2006	Respectfully submitted, By: Leslie A. Mooi (Reg. No. 37,047)
	of \$-0-	and charge any	e Commissioner is hereby authorized to charge the above-referenced fees y additional fees or credit any overpayment associated with this osit Account No. <u>08-1641 (Attorney's Docket No. 39780-1618P2C34)</u> .
	C.		0 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with other papers filed together with this statement.
	B.	a petition unde submitted here	r 37 C.F.R. §1.97(d) requesting consideration of this statement is with; and
	A.	a certification a	as specified in §1.97(e) is completed below; and
	37 C.F. office a fee, the	ction under §1.	this statement is being filed after the mailing date of the earlier of a final 113 or a notice of allowance under §1.311, but before payment of the issue
			as set forth in §1.17(p) is authorized below, enclosed, or included with the per papers filed together with this statement.
		a certification a	as specified in §1.97(e) is provided below; or
	filing d stage as action of	ate of a national set forth in §1. on the merits, but	this statement is being filed after the latest of: (1) three months beyond the application; (2) three months beyond the date of entry of the national 491 in an international application; or (3) the mailing date of a first Office at before the mailing date of the earlier of a final office action under §1.113 then:
		(4) of a rec	It is being filed before the mailing of a first Office Action after the filing quest for continued examination under § 1.114.
		(3) merits	It is being filed before the mail date of the first Office Action on the
		(2)	It is being filed within 3 months of entry of a national stage OR
		(1) than a	It is being filed within 3 months of the application filing date and is other continued prosecution application under § 1.53(d) OR
\boxtimes	This sta	atement qualifie	s under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

275 Middlefield Road Menlo Park, California 94025-3506

Telephone: (650) 324-7000 Facsimile: (650) 324-0638

Sheet 1 of 8 Application Serial No. TO-1449 Attorney's Docket No. 09/902.713 39780-1618P2C34 DISCLOSURE STATEMENT Applicant(s) Audrey Goddard et al. **Group Art Unit:** Filing Date: 1646 July 10, 2001 (use several sheets if necessary) U.S. PATENT DOCUMENTS Filing Date Class Subclass Date Document No. Name Ref. Examiner (if appropriate) Initials No. FOREIGN PATENT DOCUMENTS **Translation** Class Subclass Document No. Name Ref. Date Examiner YES Initials No. OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Title Ref. Examiner Initials No. Abe, N., et al., "An Increased High-Mobility Group A2 Expression Level is Associated with malignant Phenotype in 1. Pancreatic Exocrine Tissue," Br J Cancer - 89(11):2104-9 (2003) Abstract. Ando, M., et al., "Selective Apoptosis of Natural Killer-Cell Tumours by I-Asparaginase," Br J Haematol., - 130(6):860-8 2. (2005) Abstract. Aust, G., et al., "Human Thyroid Carcinoma Cell Lines and Normal Thyrocytes: Expression and Regulation of Matrix 3. Metalloproteinase Inhibitor-1 Messenger-RNA and Protein," Thyroid - 7(5):713-24 (1997) Abstract. Barnes, V.L., et al., " Expression of Embryonic Fibronectin Isoform EllIA Parallels Alpha-Smooth Muscle Actin in 4. Maturing and Diseased Kidney," J Histochem Cytochem. - 47(6):787-98 (1999) Abstract. Bea, S., et al., "BMI-1 Gene Amplification and Overexpression in Hematological Malignancies Occur Mainly in Mantle 5. Cell Lymphonas," Cancer Res. - 61(6):2409-12 (2001) Abstract. Blaschke, V., et al., "Rapid Quantitation of Proinflammatory and Chemoattractant Cytokine Expression in Small Tissue Samples and Monocyte-Derived Dendritic Cells: Validation of a New Real-Time RT-PCR Technology," J Immunol 6. Methods. - 246(1-2):79-90 (2000) Abstract. Buckley, A.R., et al., "Butyrate-Induced Reversal of Dexamethasone Resistance in Autonomouse Rat Nb2 Lymphoma 7. Cells," Apoptosis. - 2(6):518-28 (1997) Abstract. Caberlotto, L. et al.,"Alterations in Neuropeptide Y Levels and Y1 Binding Sites in the Flinders Sensitive Line Rats, A 8. Genetic Animal Model of Depression," Neurosci Lett. - 265(3):191-4 (1999) Abstract. Caberlotto, L., et al., "Neurokinin 1 Receptor and Relative Abundance of the Short and Long Isoforms in the Human 9. Brain," Eur J Neurosci. - 17(9):1736-46 (2003) Abstract. Choi, D., et al., "Characterization of Cyclin D2 Expression in Human Endometrium," J Soc Gynecol Investig. - 9(1):41-6 10. (2002) Abstract. Couvelard, A., et al., "Human Chorionic Gonadotrophin Beta Expression in Malignant Barrett's Oesophagus," Virchows 11. Arch. - 445(3):279-84 (2004) Abstract. Dagenais, A., et al., "Downregulation of EnaC Activity and Expression by TNF-Alpha in Alveolar Epithelial Cells," Am J. 12. Physio Lung Cell Mol Physiol. - 286(2):L301-11 (2004) Abstract. De Boer, C.J., et al., "Involement of the CCNDI Gene in Hairy Cell Leukemia," Ann Oncol. - 7(3):251-6 (1996) Abstract. 13. Debieve, F., et al., "Inhibin and Activin Production and Subunit Expression in Human Placental Cells Cultured in Vitro," 14. Mol Hum Reprod. - 6(8):743-9 (2000) Abstract. Dong, Z., et al., "Expression of Membrane-Type Matrix Metalloproteinases 4, 5, and 6 in Mouse Corneas Infected with P. 15. Aeruginosa," Invest Opthalmol Vis Sci - 42(13):3223- (2001) Abstract.

EXAMINER:	DATE CONSIDERED:
·	
EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a copy of this form with next of	forms with MPEP 609. Draw a line through the citation if not in
*If an asterisk is placed beside the reference number, a copy is not provi	ded because the reference was previously cited by or submitted to the
PTO in a prior application that is identical in the statement and relied upon	on for an earlier filling date under 35 0.3.C. §120. 37 C.F.R. §1.30 (d).

		Form PTO-1449	Attorney's Docket No. 39780-1618P2C34	Application Serial No. 09/902,713
INFO	RMATIO	N DISCLOSURE STATEMENT	Applicant(s)	1 44.44-1.
""	11,11,71110	,		ey Goddard et al.
			Filing Date:	Group Art Unit:
	(use sev	reral sheets if necessary)	July 10, 2001	1646
PEN	<u> </u>	(including a	OTHER DOCUMENTS author, title, date, pertinent pages, etc)
ע	7	Duchrow, M., et al., "Assessment o	f Proliferative Activity in Colorectal Ca eaction (RT-PCR)," <i>Cancer Invest.</i> - <u>1</u> 9	arcinomas by Quantitative Reverse 9(6):588-96 (2001) Abstract.
AUG 21 2000	8 /7.	Dyer, J., et al., "Molecular Characte	risation of Carbohydrate Digestion an Abstract.	nd Absorption in Equine Small Intestine,"
ENT & TRADE	18.	Egwuagu, C.E., et al., "Suppressors Implications for Th Cell Lineage Co	s of Cytokine Signaling Proteins are D mmitment and Maintenance," <i>J Immu</i>	ifferentially Expressed in Th1 and Th2 Cells: nol 168(7):3181-7 (2002) Abstract.
	19.	El-Ghrably, I.A., et al., "Intravitreal Vitreoretinopathy." Br J Opthalmol	nvading Cells Contribute to Vitreal Cy 85(4):461-70 (2001) Abstract.	rtokine Milieu in Proliferative
100 1	20.	Eleore, L., et al., "Modulation of the Transporter 2 in the Rat Facial Nuc	Glutamatergic Receptors (AMPA and leus after Axotomy," Neuroscience	<u>136(1)</u> :147-60 (2005) Abstract.
	21.	Forsberg, H., et al., "Altered Levels Radic Res 24(6):451-9 (1996) Abs	of Scavenging Enzymes in Embryos stract.	Subjected to a Diabetic Environment," Free
	22.	Freyschuss, B., et al., "Induction of	the Estrogen Receptor by Growth Hortes," <i>Endocrinology</i> - <u>133(4)</u> :1548-54	rmone and Glucocorticoid Substitution in (1993) Abstract.
	23.	Fu, K., et al., "Cyclin D1-Negative N Profiling." Blood - 106(13):4315-21	lantle Cell Lymphoma: A Clinocopath (2005) Abstract.	ologic Study Based on Gene Expression
· · ·	24.	Fuchs, A.R., et al., "Oxytocin Receptor Biol Reprod - 54(3):700-8 (otors in Bovine Cervix: Distrubution at 1996) Abstract.	nd Gene Expression During the Estrous
40 + ja	25. Furuta, J., et al., "Silencing of the T		hrombomodulin Gene in Human Malig	gnant Melanoma," <i>Melanoma Res.</i> - <u>15(1)</u> :15-20
26. Futcher, B., et al., "A Sampling of		Futcher, B., et al., "A Sampling of t	he Yeast Proteome," <i>Mol Cell Biol.,</i> - <u>1</u>	
	George, J., et al., "Pre-translational Regulation of Cytochrome P450 Genes is Responsible for Disease-Specific Changes of Individual P450 Enzymes Among Patients with Cirrhosis," <i>Biochem Pharmacol.</i> - 49(7):873-81 (1995) Abstract.			ochem Pharmacol <u>49(7)</u> :873-81 (1995)
	28.	165(7):3985-91 (2000) Abstract.		lation by Protein Kinase C-alpha," <i>J immunol.</i> -
	29.	Gnatenko, D.V., et al., "Transcript F	Profiling of Human Platelets Using Mic 3 (2003) Abstract.	<u>. </u>
	30.	Godbout, R., et al., "Overexpressio Biol Chem 273(33):21161-8 (1998)	n of DEAD Box Protein (DDX1) in Neu Abstract.	roblastoma and Retinoblastoma Cell Lines," J
	31. Goldenberg, R.C., et al., "Modulati		tion of Gap Junction Mediated Intercellular Communication in TM3 Leydig Cells," <i>J</i> Abstract.	
Golebiowski, F., et al., "Expression Level of Ubc9 Protein in Rat Tissues," Acta Biochim Pol 50 Abstract.				
	33.	Grem, J.L., et al., "Thymidine Kinas Lines of the National Cancer Institu	ıte's Anticancer Drug Screen," <i>Clin Ca</i>	opyrimidine Dehydrogenase Profiles of Cell ancer Res <u>7(4)</u> :999-1009 (2001) Abstract.
	34.	Grenback, E., et al., "Galanin Pituit	ary Adenomas," <i>Regul Pept,</i> - <u>117(2)</u> :1	27-39 (2004) Abstract.
	35.	Non-Invasive and Invasive Bladder	Transitional Cell Carcinomas," Int J.	rte-Type Fatty Acid Binding Protein Correlate in Oncol <u>13(2)</u> :379-83 (1998) Abstract.
	36.	Guo, Y., et al., "The Pathogenic Ro	le of Macrophage Migration Inhibitory ı Xi Za Zhi - <u>25(6)</u> :337-40 (2002) Abstra	Factor in Acute Respiratory Distress

EXAMINER:	DATE CONSIDERED.	
EXAMINER: Initial if citation considered, whether or not the citation conconformance and not considered. Include a copy of this form with next	forms with MPEP 609. Draw a line through the citation if not in communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).		
SV 2228424 v1	01101 01100110	

		Form PTO-1449	Attorney's 39780-161	Docket No. 8P2C34	Application Serial No. 09/902,713
INFO	INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		Applicant	(s)	
a.				Audr	ey Goddard et al.
			Filing Date July 10, 20		Group Art Unit: 1646
		BERTHAM SERVICE SERVICE	OTHER DOC	CUMENTS e, pertinent pages, etc	
PE IA	A 6.	Habu, Y., et al., "Restored Expression Hyperuricemia in the Rat Kidney,"	on and Activity	of Organic Ion Transp	orters rOAT1, rOAT3 and rOCT2 after
WAR 5 1 JO.	A CORPORATION OF THE PERSON OF	Hahn, M.E., et al., "Regulation of Cy Catalytic Activity by 2,3,7,8-Tetrach Pharmacol 127(2):187-98 (1994) A	/tochrome P450 lorodibenzofur lbstract.	01A1 in Teleosts: Susta an in the Marine Fish S	ained Induction of CYP1A1 mRNA, Protein, and Stenotomus Chrysops," <i>Toxicol Appl</i>
STENT & TRI	1 37/	Radioimmunoassay," Breast Cance	er Res Treat 2	<u>4(1)</u> :71-4 (1992) Abstra	ed by pS2-mRNA Analysis and pS2-Protein oct.
	40.	Severe Asthma." Clin Exp Allergy.	- 33(2):233-40 (2	2003) Abstract.	in Sustaining Neutrophil Inflammation in
	41.	Arch Biochem Biophys 337(2):275	5-83 (1997) Abs	tract.	parative Analysis of Polymorphic Expression,"
	42.	Hedge, P., et al., "A Concise Guide			
	43.	Adenoma and Adenocarcinoma." In	nt J Cance 11	3(2):198-206 (2005) Abs	proteinases 1 (TIMP-1) in Human Colorectal stract.
· · · ·	44.	Med Virol 70(4):610-6 (2003) Absti	ract.		rus Infection of Human Endothelial Cells," J
	45.	(1992) Abstract.			Quantitative Study," Mod Pathol 5(3):250-6
	40. Immunohistochemistry," Leuk Lyn		phoma, 44(8):1	385-94 (2003) Abstract	tle Cell Lymphoma: Comparison with FISH and
Husain, I., et al., "Elevation of Topoisomerase I Messenger RNA, Protein, and Demonstration of Tumor-Type Specificity and Implications for Cancer Cher (1994) Abstract.			nemotherapy," <i>Cancer Res.</i> - <u>54(2)</u> :539-46		
	48.	Prognosis in Colorectal Carcinoma	." J Cancer Res	s Clin Oncol <u>130(12)</u> :	er pKi-67 is Correlated with Favorable 749-56 (2004) Abstract.
	49.	Kidney Cells." Am J Physiol Cell Ph	hysiol 281(4):	C1396-402 (2001) Abst	sponse in Transfected Human Embryonic ract.
	50.	Retina." Int J Biol 37(3):417-23 (19	993) Abstract.		owth Factor (aFGF) Expression in Bovine
	51.	CDC25A in Mice Regenerating Live	rs," Hepatology	/ - 35 <u>(5)</u> :1063-71 (2002)	e Levels and the Intracellular Localization of Abstract.
	52.	Abstract.	•		noma," <i>Tumour Biol.</i> - <u>25(4)</u> :161-71 (2004)
	53.	Human Tissues." Int J. Cancer - 920	(6):856-60 (2001) Abstract.	igen Expression in Normal and Malignant
	54.	Biol Reprod 73(4):591-7 (2005) Ab	stract.		1) in the Mouse Placenta: Fetal Protection,"
	55.	Progesterone Receptors, in Breast 27(5):1257-63 (2005) Abstract.	Tumors: Prelin	ninary Data from Neo-A	riptase Gene and Protein, and of Estrogen amd Adjuvant Chemotherapy," Int J Oncol.
	56.	Khal, J., et al., "Expression of the U <i>J Cancer</i> - <u>93(7)</u> :774-80 (2005), Abs	Ibiquitin-Protea stract.	Isome Pathway and Mu	uscle Loss in Experimental Cancer Cachexi," <i>Br</i>
EXAMINE	R:	,		DATE CONSIDERED:	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in
conformance and not considered. Include a copy of this form with next communication to applicant.
*If an asterick is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the
PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).
SV 2228424 v1
5V 2220424 VI

		Form PTO-1449	Attorney's Docket No. 39780-1618P2C34	Application Serial No. 09/902,713
INFO	RMATIC	N DISCLOSURE STATEMENT	Applicant(s)	03/302,770
IN ORMATION DISSESSORE STATEMENT		NO DIOGEOGOTAL OTAL EMELLA	Audrey Goddard et al.	
· · · · · · · · · · · · · · · · · · ·			Filing Date:	Group Art Unit:
(use sev	veral sheets if necessary)	July 10, 2001	1646
			OTHER DOCUMENTS	
QE HO		(including a	outhor, title, date, pertinent pages, etc	<u> </u>
oole	w.Y.	Int J. Biochem Cell Biol 37(10):21	96-206 (2005) Abstract.	I Muscle of Cancer Patients with Weight Loss,"
A10 21 2000	<u>.</u>	Distinct mRNAs," J Biol Chem 27	9(24):25574-81 (2004) Abstract.	1beta in the Lung caused by Expression of
ATENTATRIS	59.	Kommoss, F., et al., "Oncogene and 155:19-24 (1992) Abstract.	d Growth Factor Expression in Ovaria	n Cancer," Acta Obstet Gynecol Scand Suppl
TA III	60.	Kumar, U., et al., "Somatostatin Red Subtypes 1-5 and Correlation with I	ceptors in Primary Human Breast Can Receptor Protein Expression and Tum	cer: Quantitative Analysis of mRNA for or Pathology," <i>Breast Cancer Res. Treat.</i> -
	61.	Leukemia Cells," Proteomics - 5(4):	894-906 (2005) Abstract.	of CpG-ODN on Human THP-1 Monocytic
	62.	Landmark, B.F., et al., "Cellular Loc Protein Kinase in Rat Testis," J Rep	ation and Age-dependent Changes of prod Fertil 99(2):323-34 (1993) Abstra	the regulatory Subunits of cAMP-dependent act.
	62.	Lassmann, S., et al., "Quantification	of CK20 Gene and Protein Expression	on in Colorectal Cancer by RT-PCR and Pathol <u>198(2)</u> :198-206 (2002) Abstract.
	63.	Legrand, O., et al., "Expression of t Peripheral Blood and Bone Marrow	he Multidrug Resistance-Associated F Haemopoietic Cells," <i>Br J, Haematol.</i>	Protein (MRP) mRNA and Protein in Normal - 94(1):23-33 (1996) Abstract.
	64.	Lemstrom, K.B., et al., "Vascular Er 105(21):2524-30 (2002) Abstract.	ndothelial Growth Factor Enhances Ca	ardiac Allograft Arteriosclerosis," Circulation -
	65.	Li, Z.B., et al., "Enhanced Expression Experimental Acute Cerebral Ischel	mia," <i>Biochem Biophys Res Commun</i>	ndem-Pore Domain Potassium Channels in Rat <u>327(4)</u> :1163-9 (2005) Abstract.
- :	66.	Li, Y., et al., "Retinal Preconditionin 44(3):1299-304 (2003) Abstract.	g and the Induction of Heat-Shock Pr	otein 27," Invest Ophthalmol Vis Sci
	67.	Lindberg, P., et al., "Increasing Exp 2 in Dog Gingival Tissues with Prog	ressive Inflammation," Arch Oral Bio	ator and Plasminogen Activator Inhibitor Type I 46(1):23-31 (2001) Abstract.
	68.	Macabeo-Ong, M., et al., "Effect of I Reaction Analyses," 15(9):979-87 (2	Duration of Fixation on Quantitative R	everse Transcription Polymerase Chain
	69.	Maruyama, H., et al., "Id-1 and Id-2 and Pancreatitis." Am J Pathol 155(3):	are Overexpressed in Pancreatic Cand 815-22 (1999) Abstract.	cer and in Dysplastic Lesions in Chronic
	70.	Meehan, T.P., et al., "Tightly Regula Cells." J Mol Endocrinol 32(1):247	ted and Inducible Expression of a Yo 7-55 (2004) Abstract.	ked Hormone-Receptor Complex in HEK 293
	71.	Mendoza-Rodriguez, C.A., et al., "C During the Estrous Cycle," Mol Rep	fos and Estrogen Receptor Gene Exp rod Dev. 64(4):379-88 (2003) Abstract	ression Pattern in the Rat Uterine Epithelium t.
	72.	Meoni, P., et al., "[3H]MK-801 Bindii Distributed in Human and Rat Forel	ng and the mRNA for the NMDARI Sub prain," <i>Brain Res Mol Res.</i> - <u>54(1)</u> :13-2	ounit of the NMDA Receptor are Differentially 3 (1998) Abstract.
	73.	Mezzano, S.A., et al., "Overexpress Membranous Nephropathy," Kiney	ion of Chemokines, Fibrogenic Cytoki Int 57(1):147-58 (2000) Abstract.	nes, and Myofibroblasts in Human
••	74.	Mingrone, G., et al., "Decreased Un Obese Subjects." Obes Res 11(5)	coupling Protein Expression and Intra):632-40 (2003) Abstract.	amyocytic Triglyceride Depletion in Formerly
	75.	Miralles, C.P., et al., "Differential Ex GABAA/benzodiazenine Receptors,	pression of the Short and Long Form: " Brain Res Mol Res 24(1-4):129-39	(1994) Abstract.
	76.	Mizrachi, D., et al.,"Follicle-stimulat	ing Hormone Receptor and Its Messe	nger Ribonucleic Acid are Present in the
EXAMINER			DATE CONSIDERED:	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in
conformance and not considered. Include a copy of this form with next communication to applicant.
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the
PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).
SV 2228424 v1

1		Form PTO-1449	Attorney's Docket No.	Application Serial No.	
	INFORMATION DISCLOSURE STATEMENT		39780-1618P2C34	09/902,713	
INFO			Applicant(s) Audrey Goddard et al.		
			Filing Date:	Group Art Unit:	
	(use several sheets if necessary)		July 10, 2001	1646	
	100000	Bovine Cervix and Can Regulate C	ervical Prostanoid Synthesis," Biol Re	prod <u>61(3)</u> :776-84 (1999) Abstract.	
			OTHER DOCUMENTS		
OE HAR	.\	(including	author, title, date, pertinent pages, etc		
2006	12 77.	Monaghan, P., et al., "The Alpha(v)	beta6 Integrin Receptor for Foot-and-l Is Targeted in Cattle," <i>J Gen Virol.</i> - <u>86</u>	Mouth Disease Virus is Expressed 6(Pt 10):2769-80 (2005) Abstract.	
100	<u> </u>	Montuori, N., et al., "Urokinase-Med	diated Posttranscriptional Regualtion	of Urokinase-Receptor Expression in Non	
100	₹ /78.	Small Cell Lung Carcinoma," Int J	<i>Cancer</i> - 105(3):353-60 (2003) Abstract	<u> </u>	
TENT & TRACE	79.	MMP, MMP-2 and MMP-9 in Human	Glioblastomas," Int J Cancer - 106(6)	elates with Matrix Metalloproteinases MT1- :848-55 (2003) Abstract.	
	80.	Esophageal Squamous Cell Carcin	omas," Carcinogenesis - 22(10):1615-	ssion of the HLA Class I Genes in Human 23 (2001) Abstract.	
	81.	Hum Pathol 34(7):639-45 (2003) A	bstract.	HER2/neu Oncogene in Synovial Sarcoma,"	
	82.	Tissue," Biochem Biophys Res Co.	<i>mmun.</i> - <u>214(3)</u> :1009-14 (1995) Abstrac	n Well Healing and Chronic Human Wound ct.	
	83.	invasive and Invasive Human Trans	sitional Cell Carcincomas," <i>Mol Cell P</i>	ripts, and Proteins Levels in Pairs of Non- roteomics 1(1):37-45 (2002) Abstract.	
	84.	Orntoft, T.F., et al. "Genome-Wide Invasive and Invasive Human Trans	Study of Gene Copy Numbers, Transc sitional Cell Carcinomas," <i>Molecular &</i>	ripts, and Protein Levels in Pairs of Non- 3. Cellular Proteomics – <u>1</u> :37-45 (2002).	
	85.	Pachmann, K., et al., "Expression of by in Situ Amplification." Br J. Hae	of bcr-abl mRNA in Individual Chronic matol - 112(3):749-59 (2001) Abstract.	Myelogenous Leukaemia Cells as determined	
	86.	Pairon, J.C., et al., "Cell Localization Induction with 3-Methylcholanthren Biol 11(4):386-96 (1994) Abstract	on and Regulation of Expression of Cy ne Using mRNA Hybridization and Imm	tochrome P450 1A1 and 2B1 in Rat Lung after nunohistochemistry," <i>Am J Respir Cell Mol</i>	
	87.	of Somatostatin Receptor Type 2 in Abstract.	nunohistochemical and Reverse Transcriptase Polymerase Chain Reaction Analysis in Neuroendocrine Tumors of the Lung," <i>Diagn Mol Pathol.</i> - <u>9(1)</u> :47-57 (2000)		
- 41	88.	Papotti, M., et al., "Expression of S	mmunohistochemical and Reverse-Tra	Cases if Gastrointestinal and Pancreatic anscriptase Polymerase Chain Reaction	
	89.	Paredes, J., et al., "P-Cadherin Ove is Associated with CDH3 Promoter	erexpression is an Indicator of Clinical Hypomethylation," <i>Clin Cancer Res.</i> -	Outcome in Invasive Breast Carcinomas and 11(16):5869-77 (2005) Abstract.	
	90.	Politis, I., et al., "Mammary-Derived Different Physiological States of the	d Growth Inhibitor Protein and Messenger Ribonucleic Acid Concentrations in ne Gland," <i>J Dairy Sci.</i> - <u>75(6)</u> :1423-9 (1992) Abstract.		
	91.	Preesman, A.H., et al., "T-Cell Rece Hodgkin's Lymphomas," J Invest L	eptor V Beta-family Usage in Primary (Dermatol <u>99(5)</u> :587-93 (1992) Abstrac	Cutaneous and Primary Nodal T-cell non- et.	
	92.	Pullig, O., et al., "Matrilin-3 in Huma Cartilage - 10(4):253-63 (2002) Abst	an Articular Cartilage: Increased Expr	ession in Osteoarthritis," Osteoarthritis	
	93.	Rey, C., et al., "Up-regulation of Mi Factor Alpha in Testicular Leydig C (2000) Abstract.	tochondrial Peripheral Benzodiazepin Cells. Possible Involvement in Cell Sur	e Receptor Expression by Tumor Necrosis vival," <i>Biochem Pharmacol.</i> - <u>60(11)</u> :1636-46	
	94.	Cervical Cancer," Am J. Clin Patho	<i>l.</i> - 120(5):691-8 (2003) Abstract.	ates to the Malignant Transformation of	
	95.	Sasaki, T., et al., "Expression and I	Distribution of Laminin Alpha1 and Alp	pha2 Chains in Embryonic and Adult Mouse	
EXAMINE	R:		DATE CONSIDERED:	***	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filling date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

		Form PTO-1449	Attorney's Docket No. 39780-1618P2C34	Application Serial No. 09/902,713	
INFO	INFORMATION DISCLOSURE STATEMENT	Applicant(s)			
				rey Goddard et al. Group Art Unit:	
]:	use sev	eral sheets if necessary)	Filing Date: July 10, 2001	1646	
		Tissues: An Immunochemical Appr	oach," <i>Exp Cell Res.</i> - <u>275(2)</u> :189-99 (2002) Abstract.	
PE MAG		(including	OTHER DOCUMENTS author, title, date, pertinent pages, etc)	
416 5 1 3006	12 6.	Biol Chem 279(25):26581-7 (2004)	Abstract.	me B Expression in Human Lymphocytes," J	
·1	9 /7.	104(9):2936-9 (2004) Abstract.	ession Parallels its mRNA level in no	·	
TENT & TRACE	98.	Glucose Transporter Isoforms in No. 1368(1):129-36 (1998) Abstract.	ormal Rat Tissues and the Malignant	pt Levels of Hexokinase Isozymes and Tumor Cell Line AH130," <i>Biochim Biophys Acta</i>	
	99.	Silvers, A.L., et al., "UVA Irradiation AP-1 Family Memebers in the Huma Abstract.	an Keratinocyte Cell Line HaCat," <i>Pho</i>	ein-1 is Correlated with Induced Expression of tochem Photbiol 75(3):302-10 (2002)	
	100.	Localization." Am J. Physiol 267(yl Aminopeptidase (aminopeptidase <i>i</i> 4 Pt 2):F546-57 (1994) Abstract.	<u> </u>	
	101.	Cyclooxgenase-2 Isoform in Cultur	ed Amnion WISH Cells," J Interferon (staglandin E2 EP1 Receptor Subtype and the Cytokine Res 18(12):1039-44 (1998) Abstract.	
	102.	Drug Metabolites." Skin Pharmacol	Appl Skin Physiol <u>16(3)</u> :143-50 (200	rance of Glucocorticord Receptor Isoforms and 03) Abstract.	
	103.	Interfering RNAs." J Biol Chem - 27	ition of AQP1 Water Channels in Isolated Rat Intrahepatic Bile Duct Units by Small [8(8):6268-74 (2003) Abstract.		
	104.	Cancer Res 53(4):878-83 (1993) A	bstract.	man Prostate: Benign and Malignant Tissue,"	
	105.	Reticulum Protein and Gene Expres	ssion," <i>J Urol.</i> - 164(3Pt 2):1026-30 (20	let Obstruction on Sarcoplasmic Endoplasmic 000) Abstract.	
	106.	Correlation with Nuetrophil Accum	ulation and E-Selectin Expression," J	s of Normal Human Skin after UVB Exposure: Invest Dermatol <u>108(5)</u> :763-8 (1997) Abstract.	
	107.	Strutz, F., et al., "Basic Fibroblast C Mediate Acutocrine Fibroblast Prol	Growth Factor Expression is Increased in Human Renal Fibrogenesis and May liferation," <i>Kidney Int.</i> - <u>57(4)</u> :1521-38 (2000) Abstract.		
	108.	Takahashi, K., et al., "Adiposity Ele Mice." J Biol. Chem 278(47):4665	vates Plasma MCP-1 Levels Leading t 4-60 (2003) Abstract.	to the Increased CD11b-Positive Monocytes in	
	109.	Takimoto, Y., et al., "Augmented Ex Decreases Heart Rate During Acute	pression of Neuronal Nitric Oxide Syle Myocardial Infarction in Rats," <i>Circu</i>	nthase in the Atria Parasympthetically lation - <u>105(4)</u> :490-6 (2002) Abstract.	
	Telek, G., et al., "Differential Upregu		ulation of Cellular Adhesion Molecules at the Sites of Oxidative Stress in J Surg Res 96(1):56-67 (2001) Abstract.		
Timchenko, L., et al., "Myotonic Dystrophy: An Unstable C 6(1):13-9 (1995) Abstract.		strophy: An Unstable CTG Repeat in a	a Protein Kinase Gene," Semin Cell Biol		
	112.	Torronen, R., et al., "Induction of C Chemicals," Chem Biol. Interact 8	33(2):107-19 (1992) Abstract.	e Mouse Hepatoma Cell Line Hepa-1 by Various	
	113.	Ullmannova, V., et al., "Relationshi Leukemia Cell Lines." Leuk Res 2	p Between Cyclin D1 and p21 (Waf1/C 27(12):1115-23 (2003) Abstract.	ip1) During Differentiation of Human Myeloid	
	Van Beers, E.H., et al., "Intestinal Carbamoyl Phosphate Synthase I in Human and Rat. Expression during Development Shows Species Differences and Mosaic Expression in Duodenum of Both Species," J Histochem Cytochem 40 (1998) Abstract.		Iman and Rat. Expression during Development h Species," <i>J Histochem Cytochem.</i> - 46(2):231-		

EXAMINER:	DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a copy of this form with next co	rms with MPEP 609. Draw a line through the citation if not in or mmunication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).		
SV 2228424 v1	Tot all earlier thing date direct 55 6.5.6. § 125. 67 6.1 M. § 100 (c).	

Form PTO-1449			Attorney's Docket No.	Application Serial No.		
INFORMATION DISCLOSURE STATEMENT			39780-1618P2C34 Applicant(s)	09/902,713		
			Audrey Goddard et al.			
	· · · · · · · · · · · · · · · · · · ·	and shorts if personny	Filing Date: July 10, 2001	Group Art Unit: 1646		
	use sev	eral sheets if necessary)	OTHER DOCUMENTS			
DE W		(including	author, title, date, pertinent pages, etc			
· · · · · ·	115.	Van Der Wilt, C.L., et al., "Expressi	on of Deoxycytidine Kinase in Leukae	mic Cells Compared with Solid Tumour Cell		
ne 51 500e	116.	Walmer, D.K., et al. "Malignant Transformation of the Human Endometrium is associated with Overexpression of				
AT & TRADELL	117.					
CETHA	118.	Wang, J., et al., "Cell Proliferation in Human Soft Tissue Tumors Correlates with Platelet-derived Growth Factor B Chain Expression: An Immunohistochemical and in Situ Hybridization Study," Cancer Res 54(2):560-4 (1994) Abstract.				
	119.	Wang, J., et al., "Expression of Cadherins and Catenins in Paired Tumor and Non-neoplastic Primary Prostate Cultures and Corresponding Prostatectomy Specimens," <i>Urol Res.</i> - 28(5):308-15 (2000) Abstract.				
	Wang, L.G., et al., "Down-Regulation of Prostate-Specific Antigen Expression by Finasteride through Inhibitio Complex Formation Between Androgen Receptor and Steroid Receptor-binding Consensus in the Promoter o Gene in LNCaP Cells," Cancer Res 57(4):714-9 (1997) Abstract.					
	121.	Weterman, M.A., et al., "Expression of Calcyclin in Human Melanocytic Lesions," Cancer Res 53(24):6061-6 (1993) Abstract.				
	122.	311(2):728-33 (2004) Abstract.				
	123.	Responsiveness" Uncoderie - 0(3):/33-00 (1333) Abstract.				
	124.	Zhong, W., et al., "Expression of Superoxide Dismutases, Catalase, and Glutathione Peroxidase in Glioma Cells," Free Radic Biol Med 27(11-12):1334-45 (1999) Abstract.				
	125.	Xi, L., et al., "Expression of Human Telomerase Reverse Transcriptase in Cervix Cancer and its Significance," Zhonghua Fu Chan Ke Za Zhi - 40(6):407-10 (2005) Abstract.				
	126.	Alberts, B., et al., Molecular Biology of the Cell (3rd ed. 1994) Cell 3rd at 453 Figure 9-2 of Cell 3rd Cell 3rd at 403				
	127.	Alberts, B., et al., Molecular Biology of the Cell (4 rd ed.) In Cell 4 th , Figure 6-3 on page 302 Figure 6-90 on page 364 of Cell 4 th at 364 Cell 4 th at 379				
	128.	Aust, G., et al., "Human Throid Carcinoma Cell Lines and Normal Thyrocytes: Expression and Regulation of Matrix Metalloproteinase-1 and Tissue Matrix Metalloproteinase Inhibitor-` Messenger-RNA and Protein," <i>Thyroid</i> -7(5):713-724 (1997)				
	129.	Nuciforo, P.G. et al., "Molecular and Immunohistochemical Analysis of HER2/neu Oncogene in Synovial Sarcoma," Human Pathology - 34(7):639-645 (2003)				
	130.	Gnatenko, D.V., et al., "Transcript Profiling of Human Platelets Using Microarray and Serial Analysis of Gene Expression." Blood - 101(6):2285-2293 (2003)				
	131.	Greenbaum, D., et al., "Analysis of mRNA Expression and Protein Abundance Data: An Approach for the Comparison of the Enrichment of Features in the Cellular Population of Proteins and Transcripts," <i>Bioinformatics1</i> - 18(4):585-496 (2002)				
	132.	(1998)				
	133.	Hirsch, F.R., et al., "Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology," Clinical Cancer Research - 7:5-22 (2001)				

EXAMINER:	DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in				
conformance and not considered. Include a copy of this form with next communication to applicant. *If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the				
PTO in a prior application that is identical in the statement and relied upon for an earlier filling date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).				
SV 2228424 v1				

		Form PTO-1449	Attorney's Docket No. 39780-1618P2C34	Application Serial No. 09/902,713	
INFO	ORMATIO	N DISCLOSURE STATEMENT	Applicant(s) Audrey Goddard et al.		
	(use sev	eral sheets if necessary)	Filing Date: July 10, 2001	Group Art Unit: 1646	
			OTHER DOCUMENTS		
PE		(including	author, title, date, pertinent pages, etc.)	
0	34.	Holten-Andersen, M.D., et al., "Localization of Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) in Human Colorectal Adenoma and Adenocarcinoma," Int. J. Cancerl - 113:198-206 (2005)			
AUG 2 1 201	2 35.	Kuo, C.C., et al., "A Transcriptomic and Proteomic Analysis of the Effect of CpG-ODN on Human THP-1 Monocytic Leukemia Cells," <i>Proteomics</i> - 5:894-906 (2005)			
3	136.	Lewin, B., Genes VI (1997 Genes VI at 847-848			
ENT & TRADE	137. 979 (2002)				
	Munaut, C., et al., "Vascular Endothelial Growth Factor Expression Correlates With Matrix Metalloproteinases MT MNP-2 and NMP-9 in Human Glioblastomas," Int. J. Cancer - 106:848-855 (2003)				
	139.	Wang, J., et al., "Expression of Cadherins and Catenins in Paired Tumor and non-Neoplastic Primary Prostate Cultur and Corresponding Prostatectomy Specimens," <i>Urol Resl</i> - 28:308-315 (2000)			
	Thigang, Z., et al., "Prostate Stem Cell Antigen (PSCA) Express in Human Prostate Cancer Tissues and its Potent Role in Prostate Carinogenesis and Progession of Prostate Cancer," World Journal of Surgical Oncology - 2-13 (2)				
	 				
-	 				
	-				
———	<u> </u>				

EXAMINER:	DATE CONSIDERED:					
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.						
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).						
SV 2228424 v1						